 |
 |
Thr University of Kansas Medical Center (KUMC) is a site for the Rilutek Drug study---qualified participants have early PD and are not on PD meds---This study is targeting newly diagnosed persons only. There are 43 sites participating in these Phase III drug trials altogether. Barbara Blake-Krebs [log in to unmask]